Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3593]

Resistance to immune checkpoint blocker drug linked to metabolic imbalance

Resistance to immune checkpoint blocker drug linked to metabolic imbalance

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated...

First CAR T-cell therapy targeting B cell-activating factor receptor eradicates blood cancers

First CAR T-cell therapy targeting B cell-activating factor receptor eradicates blood cancers

Cancer protocols: A new approach to predicting treatment outcomes

Cancer protocols: A new approach to predicting treatment outcomes

FDA approves pembrolizumab plus lenvatinib

FDA approves pembrolizumab plus lenvatinib

Electronic nose can sniff out which lung cancer patients will respond to immunotherapy

Electronic nose can sniff out which lung cancer patients will respond to immunotherapy

B cells linked to immunotherapy for melanoma

B cells linked to immunotherapy for melanoma

A liquid biopsy test can identify patients who may respond to immune checkpoint blockade

A liquid biopsy test can identify patients who may respond to immune checkpoint blockade

Nivolumab further demonstrates increase in overall survival in NSCLC

Nivolumab further demonstrates increase in overall survival in NSCLC

Durvalumab combined with chemotherapy improves overall survival in patients with lung cancer

Durvalumab combined with chemotherapy improves overall survival in patients with lung cancer

More from ecancer